NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds all those who purchased the publicly traded common stock and/or call options or sold put options of Applied Optoelectronics, Inc. (NASDAQ:AAOI) from July 13, 2017 through August 3, 2017, inclusive (the “Class Period”) of the important October 4, 2017 lead plaintiff deadline in the first filed class action commenced by Rosen Law Firm. The lawsuit seeks to recover damages for Applied Optoelectronics investors under the federal securities laws.
To join the Applied Optoelectronics class action, go to http://www.rosenlegal.com/cases-1182.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) a major customer was reducing its purchases of the Company’s 40G receivers; (2) the loss of this major customer’s business would have a severe negative impact on the Company’s financial performance; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 4, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1182.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



